Kurma Partners

Kurma Partners is a venture capital firm based in Paris, France, investing in healthcare and biotechnology companies primarily across Europe. It backs therapeutics, diagnostics and digital health companies, often co-founding ventures directly from academic research discoveries alongside European research institutes before also backing already-formed early-stage biotechs. The firm invests from company creation through growth-stage financing, spanning drug discovery platforms, diagnostic and digital-diagnostic solutions, and medtech, via a family of dedicated funds (biotech-focused Biofund series, a Diagnostics fund for digital health and diagnostics, and a Growth Opportunities fund for later-stage and crossover rounds). Its latest early-stage vehicle, Kurma Biofund IV, closed its first close in 2024 at €158 million, while its growth-stage vehicle, Kurma Growth Opportunities Fund, closed in 2024 at €167 million. Kurma typically invests alongside other investors and can lead or co-lead rounds, taking board seats in portfolio companies. The firm became part of the Eurazeo group, which founders should be aware of when considering its investor network and platform support. Prospective companies typically engage through direct outreach or introductions via its team of partners.